The combination of anti-PD-1 and anti-CD40 immunotherapy results in the upregulation of inducible nitric oxide synthase (iNOS) in moDCs, thereby facilitating T cell expansion and promoting anti-tumor immunity (Fig. 1), suggesting that moDCs could serve as a valuable therapeutic target for combination therapy [89]. The gene discussed is CD40; the disease is neoplasm.